Wong A G, O'Shaughnessy A D, Walker C M, Sears M R
Dept of Medicine, St Joseph's Hospital, Hamilton, Ontario, Canada.
Eur Respir J. 1997 Feb;10(2):330-6. doi: 10.1183/09031936.97.10020330.
Regular use of short-acting beta-agonists may decrease control of asthma and increase airway responsiveness to bronchoconstrictor stimuli. The aim of this study was to determine the effects of regular treatment with the long-acting beta-agonist, salmeterol, on the methacholine dose-response curve (DRC) in mild-to-moderate asthmatics. Changes in methacholine airway responsiveness were measured in 14 stable adult asthmatics, randomized in a double-blind, three-way cross-over design to receive salmeterol 50 micrograms, salbutamol 200 micrograms or placebo, each twice daily for 4 days. Two baseline methacholine DRC, were performed, one without premedication and one following a single dose of 200 micrograms salbutamol. Following 4 days of regular treatment, methacholine DRC to plateau were carried out commencing 15 min after the final dose of trial medication. There were no significant differences in mean baseline forced expiratory volume in one second (FEV1) between treatments. Four days treatment with salmeterol and salbutamol shifted the DRC to the right, but salmeterol provided less protection than salbutamol. The point of inflection of the curve from baseline moved 1.9 and 3.2 doubling doses, respectively, compared to placebo (p < or = 0.001), and the provocative concentration of methacholine required to produce a 20% fall in FEV1 (PC20) increased 1.6 and 3.1 doubling doses, respectively (p < or = 0.001). The slope of the DRC was increased slightly by both beta-agonists compared to placebo (log slope 3.11, 3.06 and 2.77 for salmeterol, salbutamol and placebo, respectively). This effect of regular salmeterol on slope was more marked in subjects with lower baseline FEV1. Maximal response plateaus did not differ between the three treatments. These results suggest that regular use either of short- or long-acting beta-agonists could increase the risk of a more precipitous asthma episode associated with "breakthrough" bronchoconstrictor responses, particularly in those with more severe initial airflow obstruction, if subjects are exposed to a sufficiently potent stimulus.
经常使用短效β受体激动剂可能会降低哮喘的控制水平,并增加气道对支气管收缩刺激的反应性。本研究的目的是确定长效β受体激动剂沙美特罗常规治疗对轻至中度哮喘患者乙酰甲胆碱剂量反应曲线(DRC)的影响。在14名病情稳定的成年哮喘患者中测量了乙酰甲胆碱气道反应性的变化,这些患者采用双盲、三交叉设计随机分组,分别接受50微克沙美特罗、200微克沙丁胺醇或安慰剂治疗,每日两次,共4天。进行了两条基线乙酰甲胆碱DRC,一条无预处理,另一条在单次给予200微克沙丁胺醇后进行。在常规治疗4天后,在试验药物最后一剂后15分钟开始进行乙酰甲胆碱DRC至平台期的测定。各治疗组之间一秒用力呼气容积(FEV1)的平均基线值无显著差异。沙美特罗和沙丁胺醇治疗4天使DRC右移,但沙美特罗提供的保护作用不如沙丁胺醇。与安慰剂相比,曲线从基线的拐点分别移动了1.9和3.2个加倍剂量(p≤0.001),使FEV1下降20%所需的乙酰甲胆碱激发浓度(PC20)分别增加了1.6和3.1个加倍剂量(p≤0.001)。与安慰剂相比,两种β受体激动剂均使DRC的斜率略有增加(沙美特罗、沙丁胺醇和安慰剂的对数斜率分别为3.11、3.06和2.77)。在基线FEV1较低的受试者中,常规沙美特罗对斜率的这种影响更为明显。三种治疗之间的最大反应平台期无差异。这些结果表明,如果受试者暴露于足够强的刺激下,经常使用短效或长效β受体激动剂可能会增加与“突破性”支气管收缩反应相关的更严重哮喘发作的风险,尤其是在那些初始气流阻塞较严重的患者中。